Pharma Focus Europe

AustinPx Boosts Drug Development Through Investments in Pharmaceutics and Manufacturing

Monday, April 08, 2024

AustinPx, a prominent contract development and manufacturing organization (CDMO) specializing in enhancing the bioavailability of orally administered small molecule drug candidates, has recently acquired advanced equipment to strengthen its early phase development and manufacturing capabilities.

The recent investments include the procurement of a 3P Innovations API capsule filling machine, an FT4 Powder Rheometer®, and the STYL’One Nano compaction simulator. These acquisitions aim to expedite timelines, enhance stability, and mitigate risks for the company and its clients.

Elizabeth Hickman, Chief Business Officer of AustinPx, emphasized the importance of adapting to the evolving demands of the pharmaceutical industry. She stated, “Continued pressure on pharma to reduce costs and shorten timelines requires CDMOs to offer services that enable doing more with less, such as API sparing development techniques and tools to streamline tech transfer from bench to the manufacturing suite.”

The 3P Innovations Fill2 Weight Gravimetric Filler is highlighted for its ability to accurately fill very low quantities of neat API into capsules and bottles, facilitating swift transition into manufacturing clinical trial materials while reducing costs.

The FT4 Powder Rheometer from Freeman Technologies provides critical insights into powder flow properties and granulation characteristics, aiding in optimizing formulations and manufacturing processes early on. This technology minimizes development timelines and production risks.

The Korsch STYL’One nano compaction simulator allows for the simulation of compression scale-up and expedites tablet development with minimal API quantities. It assesses material attributes across different grades and suppliers, reducing scale-up risks in the initial phases.

Justin Keen, Senior Vice President of Operations, emphasized the significance of these technological advancements in fostering innovation and ensuring client success. He stated, “These tools enable scientists and engineers to rapidly develop life-changing therapies with enhanced data and quality.”

With these expanded capabilities now available, AustinPx solidifies its position as a leading CDMO in the pharmaceutical industry, furthering its commitment to providing comprehensive formulation development and manufacturing solutions.

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva